Equillium_FullColor_RGB-300 - transparent.png
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
August 12, 2019 16:07 ET | Equillium
Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma
July 10, 2019 08:07 ET | Equillium
LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present at H.C. Wainwright Global Life Sciences Conference
March 28, 2019 16:07 ET | Equillium
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
February 26, 2019 16:07 ET | Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...